Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.52 |
| ▸ | ARG2 | P78540 | 4/20 | 0.47 |
| ▸ | ARG1 | P05089 | 3/20 | 0.47 |
| ▸ | NOS2 | P35228 | 5/20 | 0.46 |
| ▸ | NOS1 | P29475 | 4/20 | 0.46 |
| ▸ | NOS3 | P29474 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | OTC | P00480 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL187909 | 1.00 | GSR (0.52) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL21068053 | 1.00 | GSR (0.52) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL29067172 | 0.94 | GSR (0.48) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL30294237 | 0.94 | GSR (0.48) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL3727819 | 0.87 | GSR (0.53) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL28025400 | 0.87 | GSR (0.53) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL1932144 | 0.87 | GSR (0.53) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL457067 | 0.87 | GSR (0.53) | GSRARG2ARG1NOS2NOS1 | |
| Lysine SCHEMBL27593674 | 0.87 | GNAI3 (0.59) | GSRNOD1 | |
| Lysine SCHEMBL28088411 | 0.87 | GNAI3 (0.59) | GSRNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4391825-A1 | PET FOOD COMPOSITIONS AND METHOD FOR REDUCING METABOLITES ASSOCIATED WITH PROTEIN PUTREFACTION IN A FELINE | Hill's Pet Nutrition, Inc. (US) | 2024-07-03 | — | — | EP | claimed |
| US-20230404951-A1 | Pet Food Compositions | HILL'S PET NUTRITION, INC. (US) | 2023-12-21 | — | — | US | claimed |
| WO-2023244712-A1 | PET FOOD COMPOSITIONS AND METHOD FOR REDUCING METABOLITES ASSOCIATED WITH PROTEIN PUTREFACTION IN A FELINE | HILL'S PET NUTRITION, INC. (US) | 2023-12-21 | — | — | WO | claimed |
| US-20260022384-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2026-01-22 | — | — | US | disclosed |
| US-20250375505-A1 | COMPOSITIONS AND METHODS FOR MODIFYING BILE ACIDS TO REGULATE LIPID AND STEROID METABOLISM | UNIV CALIFORNIA (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250170224-A1 | METHODS AND COMPOSITIONS FOR TREATING MICROGLIAL DYSFUNCTION AND IMPROVING METABOLIC DYSFUNCTION | ALBERT-LUDWIGS-UNIVERSITAT FREIBURG (DE) | 2025-05-29 | — | — | US | disclosed |
| CN-119317362-A | Pet food compositions and methods for reducing metabolites associated with protein spoilage in felines | 希尔氏宠物营养品公司 | 2025-01-14 | — | — | CN | disclosed |
| EP-4429657-A1 | METHODS AND COMPOSITIONS FOR TREATING MICROGLIAL DYSFUNCTION AND IMPROVING METABOLIC DYSFUNCTION | Ultimate Medicine AG (CH) | 2024-09-18 | — | — | EP | disclosed |
| EP-4391825-A1 | PET FOOD COMPOSITIONS AND METHOD FOR REDUCING METABOLITES ASSOCIATED WITH PROTEIN PUTREFACTION IN A FELINE | Hill's Pet Nutrition, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| US-11872262-B2 | Means and methods for treating bacterial infections | VIB VZW (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11872262-B2 | Means and methods for treating bacterial infections | VIB VZW (BE) | 2024-01-16 | — | — | US | disclosed |
| US-8202892-B2 | Advanced glycation end products as active ingredients | HENKEL AG & CO. KGAA (DE) | 2012-06-19 | — | — | US | disclosed |
| US-8202892-B2 | Advanced glycation end products as active ingredients | HENKEL AG & CO. KGAA (DE) | 2012-06-19 | — | — | US | disclosed |
| WO-2011131474-A2 | SKIN-GENTLE DEODORANTS AND ANTIPERSPIRANTS | HENKEL AG & CO. KGAA (DE) | 2011-10-27 | — | — | WO | disclosed |
| WO-2010102863-A1 | BIOLOGICALLY DEGRADABLE BUILDER SUBSTANCES AND CO-TENSIDES | HENKEL AG & CO. KGAA (DE) | 2010-09-16 | — | — | WO | disclosed |
| US-20100204176-A1 | ADVANCED GLYCATION END PRODUCTS AS ACTIVE INGREDIENTS | HENKEL AG & CO. KGAA (DE) | 2010-08-12 | — | — | US | disclosed |
| US-20100204176-A1 | ADVANCED GLYCATION END PRODUCTS AS ACTIVE INGREDIENTS | HENKEL AG & CO. KGAA (DE) | 2010-08-12 | — | — | US | disclosed |
| WO-2010063678-A2 | NOVEL DEODORANTS AND ANTIPERSPIRANTS HAVING HAIR GROWTH INHIBITING EFFECT | HENKEL AG & CO. KGAA (DE) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010063673-A2 | NOVEL COSMETIC COMPOSITIONS HAVING HAIR GROWTH INHIBITING EFFECT | HENKEL AG & CO. KGAA (DE) | 2010-06-10 | — | — | WO | disclosed |
| WO-2009007257-A2 | ADVANCED GLYCATION END PRODUCTS AS ACTIVE INGREDIENTS | HENKEL AG & CO. KGAA (DE) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250375505-A1 | COMPOSITIONS AND METHODS FOR MODIFYING BILE ACIDS TO REGULATE LIPID AND STEROID METABOLISM | CYP27A1, LIPC, CYP46A1 | GSR 269/4885ARG2 1108/4885ARG1 2605/4885 |
| US-20100204176-A1 | ADVANCED GLYCATION END PRODUCTS AS ACTIVE INGREDIENTS | AGER, GLA, TYR | GSR 630/4885ARG2 65/4885ARG1 8/4885 |
| US-11872262-B2 | Means and methods for treating bacterial infections | VIP, MMP8, SLC11A2 | GSR 1416/4885ARG2 359/4885ARG1 40/4885 |
| US-20260022384-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | ASNS, AARS1, NARS1 | GSR 2917/4885ARG2 2573/4885ARG1 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.